Integer Holdings Corporation · NYSE:ITGR

Integer — 42nd Annual J.P. Morgan Healthcare Conference (January 2024)

17 slides from Integer's conference presentation, Jan 10, 2024

  1. Slide 1: 42nd Annual JP Morgan Healthcare Conference

    42nd Annual JP Morgan Healthcare Conference January 10, 2024 ITGR: JPM Conference / January 10, 2024 / Page 1

  2. Slide 2: Presentation of Financial Information & Forward-Looking Statements

    Presentation of Financial Information & Forward-Looking Statements Important Information This presentation contains summarized information concerning Integer Holdings Corporation (the “Company”) and its business, operations, financial performance and trends. The historical financial and operating da

  3. Slide 3: Integer Snapshot

    Integer Snapshot Integer is one of the largest medical device outsource manufacturers in the world Differentiated Global Footprint 2023 Sales Outlook ~$1.6 Billion at Midpoint Medical Sales (97%) Non-Medical (3%) % Sales by End 52% 39% 6% 3% Markets(1) Portable Electrochem Cardio & CRM & Medical & V

  4. Slide 4: Integer Investment Thesis

    Integer Investment Thesis Strategy Financial Objectives •1 Sales growth 200 basis points above market •2 Operating profit 2x sales growth rate •3 Debt leverage 2.5x – 3.5x Resilient Compelling Performance Financial Business Model Strategy for Growth Culture Strength  Sustainable mid-single-digit 

  5. Slide 5: Integer’s Strategy Journey

    Integer’s Strategy Journey 2017 2018 2019 2020 2021 2022 2023 Portfolio Divested AS&O Strategy Strategy Developed Portfolio Strategy Launched Initiated Partial Portable Medical Exit Portfolio Capability & Capacity Expansion  Product Line Growth Teams Product Line Strategies Strategy Strategies Form

  6. Slide 6: New Revenue Generation Cycle Times

    New Revenue Generation Cycle Times Time to Manufacturing Integer Revenue Profile Across Cycle Ramp Existing Product Transfers Process Reg Begin Dev 0 – 6 Manufacturing 1 – 2+ 1 – 2 years months Ramp Years New 510k Products (Class II) Developed w/ Customers Development  Clinical Manufacturing Ramp

  7. Slide 7: C&V Targeted Market Strategy to Drive Sustained Growth

    C&V Targeted Market Strategy to Drive Sustained Growth Integer Investment Interventional Focus Cardiology Peripheral Vascular Electro- physiology Neurovascular Pulsed Field Structural Renal Ablation Heart Growth Denervation Curve Heart Pumps Low Technology Maturity High Target Growth Markets Structu

  8. Slide 8: CRM&N Targeted Market Strategy to Drive Sustained Growth

    CRM&N Targeted Market Strategy to Drive Sustained Growth Integer Investment Conventional Focus Traditional Pain Mgmt. CRM Pacing (SCS) Cochlear Epilepsy Incontinence Cardiac Monitoring Neuromodulation Parkinson's Dual- Single-Chamber Leadless CRM Chamber Pain Mgmt. CRM Sleep Leadless (Emerging) Apne

  9. Slide 9: Growth Starts with Product Development

    Growth Starts with Product Development Product development sales Strategy delivering mix shift to +230% since strategy launch high-growth markets ~20% ~20% ~50% Mature ~80% ~28% 3 – 5+ Emerging / ~50% Years Growth 2021 2017 2023 2017 2021 2023 Development Sales Strategy focused on being designed int

  10. Slide 10: Capacity & Capability to Continue Acquisition Strategy

    Capacity & Capability to Continue Acquisition Strategy ($ in millions) Annual Acquisition Acquisition Criteria Capacity $250 - $300 Growth Market Focus Funding Sources Differentiated Capabilities Annual Free Cash Flow Revenue Growth + Organic growth and Accretive Margin Profile acquired EBITDA High

  11. Slide 11: Executing Targeted Inorganic Growth Strategy

    Executing Targeted Inorganic Growth Strategy Four Acquisitions in last 25 Months Jan 2024 Oct 2023 Apr 2022 Dec 2021  Leadless pacing  Aspiration catheters  Structural heart  Electrophysiology  Neuromodulation  Thrombectomy delivery catheters  Neurovascular  Neuromodulation  Heart pumps  S

  12. Slide 12: Pulse Technologies, a Leader in Precision Micro Machining

    , a Leader in Precision Micro Machining • Stock purchase closed on January 5, 2024 Transaction • ~250 associates located in Quakertown, Pennsylvania Profile • Estimated 2023 sales of ~$42 million and 2023 adjusted EBITDA(1) of ~$11 million • Brings differentiated complex machining and manufacturing

  13. Slide 13: Brings Differentiated Expertise and Capabilities

    Brings Differentiated Expertise and Capabilities Areas of Focus CRM & Neuromodulation:  Leadless pacing  Ventricular assist  Deep brain stimulation  Pain management  Traditional pacing Cardio & Vascular:  Heart pumps  Electrophysiology (incl. PFA)  Structural heart  Peripheral vascular  In

  14. Slide 14: Executing Organic and Inorganic Sales Growth Strategy

    Executing Organic and Inorganic Sales Growth Strategy … Sustained Above Market Growth Integer Sales Growth at Market Rate 15% 13% 2016 2019 2022 2023 Future … to deliver high single digit / low double-digit sales growth ITGR: JPM Conference / January 10, 2024 / Page 14

  15. Slide 15: Integer Investment Thesis

    Integer Investment Thesis Strategy Financial Objectives •1 Sales growth 200 basis points above market •2 Operating profit 2x sales growth rate •3 Debt leverage 2.5x – 3.5x Resilient Compelling Performance Financial Business Model Strategy for Growth Culture Strength  Sustainable mid-single-digit 

  16. Slide 16: Questions?

    Questions? ITGR: JPM Conference / January 10, 2024 / Page 16

  17. Slide 17: Non-GAAP Financial Measures

    Non-GAAP Financial Measures This presentation may contain the non-GAAP financial measures defined in the table below. A GAAP reconciliation of Adjusted EBITDA to anticipated net income has not been included because Pulse Technologies has not yet completed its financial closing procedures for the thr

Integer Holdings — 42nd Annual J.P. Morgan Healthcare Conference (January 2024) on 6ix